Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof

1. A method for preparing a medicament for treating a disease selected from the group consisting of toxoplasmosis, malaria, isosporiasis, cystoisosporiasis, actinomycosis, pneumocystis jirovecii pneumonia, myelodysplastic syndromes, and amyotrophic lateral sclerosis comprising, the method comprising:

(a) preparing a suspension comprising:

(a1) a dispersed phase consisting of particles comprising a therapeutically effective quantity of at least one diaminopyrimidine compound, or derivatives or analogs thereof;

(a2) at least one pharmaceutically acceptable surfactant or solubilizing and suspending agent; and

(a3) an anhydrous dispersion medium,

wherein the dispersed phase is dispersed within the dispersion medium;

(b) placing the suspension into a cup having disposed thereon a plurality of markings, each marking corresponding to a predetermined quantity of element (a1); and

(c) using a stirrer to mix a quantity of at least one derivative of folic acid into the suspension, wherein the quantity of the derivative of folic acid corresponds to the quantity of element (a1),

thereby preparing the medicament.

2. The method of claim 1 , wherein the diaminopyrimidine compound is selected from the group consisting of pyrimethamine, trimetrexate, iclaprim, trimethoprim, 2,4-diaminopyrimidine, 4,5-diaminopyrimidine, piritrexim, and any combination thereof.

3. The method of claim 2 , wherein the diaminopyrimidine compound is pyrimethamine.

4. The method of claim 1 , wherein the derivative of folic acid is leucovorin.

5. The method of claim 1 , wherein the anhydrous dispersion medium comprises at least one vegetable oil or at least one medium chain triglyceride, or any combination thereof.

6. The method of claim 5 , wherein the vegetable oil is selected from the group consisting of castor oil, soybean oil, coconut oil, avocado oil, olive oil, almond oil, and combinations thereof.

7. The method of claim 5 , wherein the medium chain triglyceride is a triglyceride having at least two of the three fatty acids moieties that are derived from saturated open-chain acids having between 6 and 12 carbon atoms.

8. The method of claim 7 , wherein the saturated open-chain acids are selected from the group consisting of caprylic acid and caproic acid.

9. The method of claim 1 , wherein the acceptable surfactant or solubilizing and suspending agent is selected from the group consisting of non-ionic polyoxyethlene-polyoxypropylene block copolymers, a water-soluble derivative of cellulose, optionally partially cross-linked polyacrylates, polyoxyethylene sorbitan monolaurates, glyceryl distearate, triglycerol monooleate, polyoxyethylene sorbitan monopalmitates, polyoxyethylene sorbitan monostearates, and polyoxyethylene sorbitan monooleates.

10. The method of claim 9 , wherein the non-ionic polyoxyethlene-polyoxypropylene block copolymer is poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).

11. The method of claim 9 , wherein the water-soluble derivative of cellulose is selected from the group consisting of carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose.

12. The method of claim 9 , wherein the solubilizing and suspending agent is polyoxyethylene (20) sorbitan monooleate.

13. The method of claim 3 , wherein the mass concentration of pyrimethamine in the composition is between about 0.1% and about 5.0%.

14. The method of claim 1 , wherein the composition retains between about 90% and about 110% of the diaminopyrimidine compound after being stored at room temperature for each of 30, 60, 90 and 150 days and up to about 40° C. for each of 30, 60, and 90 days.

15. The method of claim 1 , wherein the quantity of element (a1) is 25 mg, 50 mg, or 75 mg.

16. A pharmaceutical kit, comprising:

(a) a container containing a suspension, wherein the suspension comprises:

(a1) a dispersed phase consisting of particles comprising a therapeutically effective quantity of at least one diaminopyrimidine compound, or derivatives or analogs thereof;

(a2) at least one pharmaceutically acceptable surfactant or solubilizing and suspending agent; and

(a3) an anhydrous dispersion medium,

wherein the dispersed phase is dispersed within the dispersion medium;

(b) a cup having disposed thereon a plurality of markings, each marking corresponding to a predetermined quantity of element (a1);

(c) at least one packet containing a quantity of a derivative of folic acid, wherein the quantity of the derivative of folic acid corresponds to the quantity of element (a1);

(d) a stirrer;

(e) a box configured to store elements (a)-(d); and

instructions for use enclosed within the box or affixed thereto.

17. The kit of claim 16 , wherein the cup has three markings, wherein each marking indicates the quantities of 25 mg, 50 mg, and 75 mg, respectively, of element (a1).

18. The kit of claim 16 , wherein the diaminopyrimidine compound is selected from the group consisting of pyrimethamine, trimetrexate, iclaprim, trimethoprim, 2,4-diaminopyrimidine, 4,5-diaminopyrimidine, piritrexim, and any combination thereof.

19. The kit of claim 18 , wherein the diaminopyrimidine compound is pyrimethamine.

20. The kit of claim 16 , wherein the derivative of folic acid is leucovorin.